<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605083</url>
  </required_header>
  <id_info>
    <org_study_id>eFT508-0001</org_study_id>
    <nct_id>NCT02605083</nct_id>
  </id_info>
  <brief_title>A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1-2 Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Effector Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Effector Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and&#xD;
      cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and&#xD;
      antitumor activity of daily oral administration of eFT508.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      eFT508 is an oral, potent and highly selective inhibitor of mitogen-activated protein kinase&#xD;
      interacting kinase (MNK) 1 and 2. Dysregulated translation of messenger RNA (mRNA) plays a&#xD;
      role in the pathogenesis of multiple solid tumors and hematological malignancies. MNK1 and&#xD;
      MNK2 integrate signals from several oncogenic and immune signaling pathways (including RAS,&#xD;
      p38 and Toll-like receptors) by phosphorylating eukaryotic initiation of factor 4E (eIF4E)&#xD;
      and key effector proteins. Phosphorylation of these regulatory proteins by MNK1 and MNK2&#xD;
      selectively regulates the stability and translation of a subset of cellular mRNA that control&#xD;
      tumor growth, the tumor microenvironment and immune signaling. Nonclinical studies indicate&#xD;
      that eFT508 shows activity against various types of solid tumors. These nonclinical studies&#xD;
      support initiation of clinical development of eFT508 in patients with cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated after determination of the RP2D, prior to opening expansion cohorts)&#xD;
  </why_stopped>
  <start_date type="Actual">December 3, 2015</start_date>
  <completion_date type="Actual">March 22, 2019</completion_date>
  <primary_completion_date type="Actual">January 11, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)/Recommended dose (RD)</measure>
    <time_frame>Up to one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to three years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE v. 4.03))</measure>
    <time_frame>Up to three year</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE v. 4.03)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of eFT508 as characterized by maximum serum concentration (Cmax)</measure>
    <time_frame>Different time points up to 336 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of eFT508 as characterized by Area Under the Curve (AUC)</measure>
    <time_frame>Different time points up to 336 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in eIF4E phosphorylation in peripheral blood cells (PBMCs)</measure>
    <time_frame>Up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor control evaluated by modified RECIST criteria v 1.1</measure>
    <time_frame>Up to three years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>eFT508</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eFT508</intervention_name>
    <description>Will be given orally once or twice daily. Each treatment cycle = 21 days.</description>
    <arm_group_label>eFT508</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          2. Pathologically documented diagnosis of advanced solid tumor malignancy that progressed&#xD;
             after appropriate prior therapy or has no potential for cure with currently available&#xD;
             treatments.&#xD;
&#xD;
          3. Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             outside of any prior radiation field.&#xD;
&#xD;
          4. At least 3 weeks post any treatments/therapies at the time of first dose.&#xD;
&#xD;
          5. Adequate bone marrow function.&#xD;
&#xD;
          6. Adequate hepatic function.&#xD;
&#xD;
          7. Adequate renal function.&#xD;
&#xD;
          8. Normal coagulation panel.&#xD;
&#xD;
          9. Negative antiviral serology.&#xD;
&#xD;
         10. Willingness to use effective contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known central nervous system malignancy.&#xD;
&#xD;
          2. Gastrointestinal disease that may interfere with drug absorption.&#xD;
&#xD;
          3. Significant cardiovascular disease.&#xD;
&#xD;
          4. Significant ECG abnormalities.&#xD;
&#xD;
          5. Ongoing risk of bleeding due to active peptic ulcer disease, bleeding diathesis, or&#xD;
             requirement for systemic anticoagulants. Use of heparin or thrombolytic agents for&#xD;
             local maintenance or clearance of a central venous catheter is permitted.&#xD;
&#xD;
          6. Ongoing systemic bacterial, fungal or viral infection (with the exception of fungal&#xD;
             infections of the skin or nails).&#xD;
&#xD;
          7. Pregnancy or breastfeeding.&#xD;
&#xD;
          8. Major surgery within 4 weeks before the start of study therapy.&#xD;
&#xD;
          9. Prior solid organ or bone marrow progenitor cell transplantation.&#xD;
&#xD;
         10. Prior therapy with any known inhibitor of MNK1 or MNK2.&#xD;
&#xD;
         11. Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids (can&#xD;
             be using topical or inhaled corticosteroids).&#xD;
&#xD;
         12. Use of drugs that might pose a risk of a drug-drug interaction within 4-7 days before&#xD;
             the start of study therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Barton, MD</last_name>
    <role>Study Director</role>
    <affiliation>Effector Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SCRI at HealthONE</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Neoplasm</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Breast</keyword>
  <keyword>Head and Neck</keyword>
  <keyword>Lung</keyword>
  <keyword>Pancreatic</keyword>
  <keyword>Hepatic</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Colon</keyword>
  <keyword>Renal</keyword>
  <keyword>Thyroid</keyword>
  <keyword>Prostate</keyword>
  <keyword>Ovarian</keyword>
  <keyword>MNK1</keyword>
  <keyword>MNK2</keyword>
  <keyword>eIF4E</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

